Remicade (infliximab) - J&J
Cimzia (certolizumab pegol) - Astellas, UCB
Rituxan (rituximab) - Roche
Humira (adalimumab) - AbbVie
tofacitinib - Generic mfg.
Jyseleca (filgotinib) - Gilead
Simponi (golimumab) - J&J
Rinvoq (upadacitinib) - AbbVie
Actemra IV (tocilizumab) - Roche, JW Pharma, Chugai Pharmaceutical
Olumiant (baricitinib) - Eli Lilly
Orencia (abatacept) - BMS
Enbrel (etanercept) - Pfizer, Amgen
Kevzara (sarilumab) - Asahi Kasei Therapeutics, Regeneron, Sanofi
https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQgpHT_izqP12iSDQb6Ly1WnJRMbzry_I1H1MUYP1KNVP0
 
Viking Huss1, 2; Martin Björklund1; Hannah Bower1; Daniela Di Giuseppe1; Bénédicte Delcoigne1; Karin Hellgren1, 3; Thomas Frisell1; Johan Askling1, 2
 
May 23, 2026
 
Prev Next